Estudio CHARM. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity. Discusión y crítica

Ítems similars

• Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy
  per: Colombo, Giorgio L, et al.
  Publicat: (2008)
• Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
  per: Preiss, David, et al.
  Publicat: (2009)
• Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
  per: Allen, Larry A., et al.
  Publicat: (2009)
• Candesartan in heart failure
  per: Ripley, Toni L, et al.
  Publicat: (2006)
• Low-Dose Digoxin and Reduction in Mortality and Morbidity in Heart Failure
  per: Ahmed, Ali, et al.
  Publicat: (2009)